Should a proton‑pump inhibitor (PPI) be administered to a patient with upper gastrointestinal symptoms and gastric wall thickening on CT before endoscopic evaluation?

Should You Give a PPI to a Patient with Upper GI Symptoms and Gastric Wall Thickening on CT Before Endoscopy?

Yes, initiate empirical PPI therapy (once daily, escalating to twice daily if needed) for patients with typical upper GI symptoms, but proceed directly to endoscopy without delay when gastric wall thickening is present on CT imaging, as this finding may represent serious pathology including malignancy that requires urgent diagnosis. 1

Clinical Approach Based on Symptom Type

For Typical GERD Symptoms (Heartburn, Regurgitation)

Start empirical PPI therapy as the first-line approach when patients present with typical reflux symptoms and no alarm features 1, 2:

• Begin with once-daily PPI (any agent: omeprazole, lansoprazole, esomeprazole, pantoprazole, rabeprazole, or dexlansoprazole) taken 30-60 minutes before a meal
• If inadequate response after 4 weeks, escalate to twice-daily dosing
• If symptoms persist after 4-8 weeks of twice-daily therapy, proceed to endoscopy 1

The evidence strongly supports this approach, with guidelines from the American College of Physicians demonstrating that empirical PPI trials are appropriate for typical symptoms, with endoscopy reserved for treatment failures 1.

Critical Exception: Presence of Gastric Wall Thickening on CT

When CT demonstrates gastric wall thickening, this changes the clinical calculus entirely. The ACR Appropriateness Criteria note that gastric wall thickening can indicate multiple serious conditions 3:

• Peptic ulcer disease with submucosal edema
• Gastritis with mucosal hyperenhancement
• Gastric malignancy (the most concerning possibility)
• Perforation risk (wall thickening shows positive likelihood ratio of 10.52 for perforation) 3

A critical pitfall: PPIs can mask early gastric cancer by healing ulcerated malignant lesions, making them endoscopically unrecognizable even to experienced endoscopists 4. This case series demonstrated that short courses of PPIs before endoscopy caused complete resolution of endoscopic signs in 7 patients with early gastric cancer, potentially delaying life-saving diagnosis 4.

When to Proceed Directly to Endoscopy (Without PPI Trial or With Concurrent PPI)

Immediate endoscopy is indicated when any of these features are present 1:

• Alarm symptoms: dysphagia, bleeding, anemia, weight loss, recurrent vomiting
• Gastric wall thickening on imaging (as in your scenario)
• Age >50 years with new-onset symptoms
• Suspected malignancy based on imaging findings

In these situations, you may initiate PPI therapy for symptom relief while arranging urgent endoscopy, but do not delay endoscopy to complete an empirical PPI trial 1.

For Extraesophageal Symptoms Without Typical GERD

The 2023 AGA guidelines provide clear direction: consider objective testing (endoscopy and pH monitoring) BEFORE initiating PPI therapy in patients with potential extraesophageal manifestations but without typical heartburn/regurgitation 5. This is because:

• PPI trials have poor diagnostic performance for extraesophageal reflux (sensitivity 71-78%, specificity only 41-54% even for typical symptoms) 5
• Symptom improvement may result from placebo effects or non-acid suppression mechanisms 5
• Empirical PPI trials in this population lead to inappropriate long-term use without confirmed diagnosis

Practical Algorithm for Your Specific Scenario

Patient with upper GI symptoms + gastric wall thickening on CT:

1. Initiate PPI therapy (once daily) for symptom control
2. Arrange urgent endoscopy (within days, not weeks) - do not wait for PPI trial completion
3. At endoscopy, obtain biopsies of any abnormal areas, particularly where wall thickening was noted on CT
4. Continue PPI pending endoscopy results
5. Adjust therapy based on endoscopic findings (erosive esophagitis, ulcer, malignancy, etc.)

Important Caveats

PPI safety considerations: While recent high-quality evidence suggests PPIs are generally safe for appropriate indications 6, 7, the absolute risk of adverse events (enteric infections, nutrient deficiencies, fractures) remains low, and benefits outweigh risks when used for legitimate indications at the lowest effective dose 2, 6, 7.

The masking effect is real: The evidence from case series demonstrates that PPIs can heal malignant gastric ulcers sufficiently to make them unrecognizable at subsequent endoscopy 4. This is why primary care physicians must resist prescribing PPIs before endoscopy in patients >45 years with new symptoms or concerning imaging findings 4.

Dosing optimization: If continuing PPI therapy, dose 30-60 minutes before meals for optimal efficacy, and taper to the lowest effective dose once symptoms are controlled 1, 2.